Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Stage I endometrial adenocarcinoma: treatment results in 835 patients.

Literature DB >> 6846429

Stage I endometrial adenocarcinoma: treatment results in 835 patients.

R J Lotocki, L J Copeland, A D DePetrillo, W Muirhead.

Abstract

A 16-year review of 835 patients with Stage I adenocarcinoma of the uterus revealed histologic grade and depth of myometrial invasion to be salient prognostic factors. Sixteen percent of patients developed recurrent disease and despite aggressive treatment, only 10% of these survived. Preoperative or postoperative radium decreased the incidence of vault recurrence.

Entities: Disease Species

Mesh：

Substances：
Estrogens

Year: 1983 PMID： 6846429 DOI： 10.1016/0002-9378(83)91042-6

Source DB: PubMed Journal: Am J Obstet Gynecol ISSN： 0002-9378 Impact factor: 8.661

Keyword Cloud
Cited

10 in total

1. Uterine smooth muscle cells increase invasive ability of endometrial carcinoma cells through tumor-stromal interaction.

Authors: Hirohisa Tsukamoto; Kiyosumi Shibata; Hiroaki Kajiyama; Mikio Terauchi; Akihiro Nawa; Fumitaka Kikkawa
Journal: Clin Exp Metastasis Date: 2007-06-21 Impact factor: 5.150

2. Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma.

Authors: H Hareyama; N Sakuragi; S Makinoda; S Fujimoto
Journal: J Clin Pathol Date: 1996-12 Impact factor: 3.411

3. Small interfering RNA-mediated knockdown of Twist attenuates the aggressive phenotypes of human endometrial carcinoma Ishikawa cells.

Authors: Yilian Pan; Xiaoyi Liu; Yong Huang
Journal: Exp Ther Med Date: 2017-09-27 Impact factor: 2.447

Review 4. Pathophysiology and management of endometrial hyperplasia and carcinoma.

Authors: Y S Fu; J C Gambone; J S Berek
Journal: West J Med Date: 1990-07

5. Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumour progression and metastasis.

Authors: D T Rein; K Roehrig; T Schöndorf; A Lazar; M Fleisch; D Niederacher; H G Bender; P Dall
Journal: J Cancer Res Clin Oncol Date: 2003-02-20 Impact factor: 4.553

6. Effect of Pelvic Lymphadenectomy on Survival in Patients with Low-Risk Early-Stage Endometrial Cancer Diagnosed Intraoperatively Using Frozen Tissue Sections: A Retrospective Analysis.

Authors: Caiyan Liu; Jianguo Zhao; Shasha Liu; Yaomei Ma; Yun Yang; Pengpeng Qu
Journal: Cancer Manag Res Date: 2020-10-29 Impact factor: 3.989

Stage I endometrial adenocarcinoma: treatment results in 835 patients.

1. Uterine smooth muscle cells increase invasive ability of endometrial carcinoma cells through tumor-stromal interaction.

2. Serum and tissue measurements of CA72-4 in patients with endometrial carcinoma.

3. Small interfering RNA-mediated knockdown of Twist attenuates the aggressive phenotypes of human endometrial carcinoma Ishikawa cells.

Review 4. Pathophysiology and management of endometrial hyperplasia and carcinoma.

5. Expression of the hyaluronan receptor RHAMM in endometrial carcinomas suggests a role in tumour progression and metastasis.

6. Effect of Pelvic Lymphadenectomy on Survival in Patients with Low-Risk Early-Stage Endometrial Cancer Diagnosed Intraoperatively Using Frozen Tissue Sections: A Retrospective Analysis.

7. Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer.

8. Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer.

9. MIIP remodels Rac1-mediated cytoskeleton structure in suppression of endometrial cancer metastasis.

10. MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α.